Planegg (pta006/04.10.2017/07:30) -
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming scientific and business development conferences:
3rd ACTC Advances in Circulating Tumour Cells
Date: 4 - 7 October 2017
Location: Rhodes, Greece
Immune Profiling Congress 2017
Date: 10 - 12 October 2017
Location: Barcelona, Spain
Dr. Kai Pinkernell, Chief Medical Officer of Medigene, will give a presentation on 11 October at 8.40 am on the topic: "Development of TCR-based adoptive T cell therapies: opportunities and challenges".
Date: 11 - 13 October 2017
Location: Yokohama, Japan
DECHEMA colloquium: Trading in cells - Lab cultures, patients, and the promise of applications
Date: 18 October 2017
Location: Berlin, Germany
Dr. Kai Pinkernell, Chief Medical Officer of Medigene, will give a presentation at 2.15 pm on the topic "Transformation of a biotech company to a developer of innovative cell-based therapeutics".
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (email@example.com). We will then delete your address from our distribution list.